Last updated on October 2017

A Safety Study of SYNT001 in Subjects With Chronic Stable Warm Autoimmune Hemolytic Anemia (WAIHA)


Brief description of study

This study is being conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and effects on warm autoimmune hemolytic anemia (WAIHA) disease activity markers of intravenous (IV) SYNT001.

Clinical Study Identifier: NCT03075878

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Syntimmune, Inc

USC - Norris Comprehensive Cancer Center
Los Angeles, CA United States
  Connect »

Syntimmune, Inc

University of California San Francisco - Outpatient Hematology Clinic/Infusion Center
San Francisco, CA United States
  Connect »

Syntimmune, Inc

Massachusetts General Hospital - Cancer Center
Boston, MA United States
  Connect »

Syntimmune, Inc

Mayo Clinic - Rochester
Rochester, MN United States
  Connect »

Syntimmune, Inc

Hospital of the University of Pennsylvania
Philadelphia, PA United States
  Connect »

Syntimmune, Inc

University of Washington Medical Center
Seattle, WA United States
  Connect »